Zero Debt / Low LeverageA zero-debt balance sheet materially reduces refinancing and interest-rate risk, giving management flexibility to invest in product development or commercial expansion over the next several quarters without immediate debt servicing constraints. It supports solvency while losses persist.

Strong Revenue ReboundA >100% TTM revenue recovery signals improving commercial traction and market acceptance of the product suite. Durable top-line growth can expand scale for consumables sales and operating leverage, improving the path to sustainable margins if the trend continues.

Specialized Microfluidics PlatformA focused product niche in single-cell microfluidics creates technical differentiation and recurring consumables demand. This specialization supports long-term customer stickiness and potential pricing power in academic and industrial lab channels.

Bears Say

Ongoing Cash BurnSubstantial negative operating and free cash flow indicates the company cannot self-fund growth and will likely need external financing within months. Repeated funding rounds can dilute shareholders and constrain strategic choices, limiting long-term capital efficiency.

Negative ProfitabilityPersisting net losses and negative margins show the business has not yet reached breakeven economics. Without sustained margin improvement, profitability risks undermining equity value and restricts reinvestment capacity for product and commercial scale.

Eroding Equity BaseA halving of equity in the span of a year reflects cumulative losses that reduce the financial buffer against shocks. A weaker capital base limits runway and increases reliance on new capital, raising execution risk during product commercialization stages.

FLUI FAQ

What was Fluicell AB’s price range in the past 12 months?

Fluicell AB lowest stock price was kr7.45 and its highest was kr30.00 in the past 12 months.

What is Fluicell AB’s market cap?

Fluicell AB’s market cap is kr18.00M.

When is Fluicell AB’s upcoming earnings report date?

Fluicell AB’s upcoming earnings report date is May 08, 2026 which is in 66 days.

How were Fluicell AB’s earnings last quarter?

Fluicell AB released its earnings results on Feb 20, 2026. The company reported kr0.074 earnings per share for the quarter, beating the consensus estimate of N/A by kr0.074.

Is Fluicell AB overvalued?

According to Wall Street analysts Fluicell AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Fluicell AB pay dividends?

Fluicell AB does not currently pay dividends.

What is Fluicell AB’s EPS estimate?

Fluicell AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Fluicell AB have?

Fluicell AB has 1,373,703 shares outstanding.

What happened to Fluicell AB’s price movement after its last earnings report?

Fluicell AB reported an EPS of kr0.074 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.789%.

Which hedge fund is a major shareholder of Fluicell AB?

Currently, no hedge funds are holding shares in SE:FLUI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Fluicell AB

Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.